Benzinga | Oct 19, 2021 06:20AM EDT

HC Wainwright & Co. Initiates Coverage On Landos Biopharma with Buy Rating, Announces Price Target of $50

HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Landos Biopharma (NASDAQ:LABP) with a Buy rating and announces Price Target of $50.